Synergistic interactions between 12-0-tetradecanoylphorbol-13-acetate (TPA) and imatinib in patients with chronic myeloid leukemia in blastic phase that is resistant to standard-dose imatinib.

Baijun Fang, Yongping Song, Zhengtao Han, Xudong Wei, Quande Lin, Xiaoxiu Zhu, Ruyu Yang, Junzhong Sun, Guofeng Tian, Xinjian Liu, Guoshun Cao, Yin Shi, Neng Nie, Dapeng Li, Robert Chunhua Zhao

Journal: Leukemia research 2007;31(10):1441-4

PMID: 17383001

Full Text on Elsevier Science View on PubMed

Abstract

We have demonstrated that 12-0-tetradecanoylphorbol-13-acetate (TPA) combined with vitamin D(3) (VD(3)) and cytosine arabinoside (Ara C) is effective and feasible for chronic myelogenous leukemia (CML) in blastic phase (BP). In the current study, the efficacy of TPA combined with inhibitor imatinib mesylate (imatinib) was investigated in patients with CML in BP that was resistant to standard-dose imatinib (400mg/day). The results suggested that TPA combined with imatinib (400mg/day) might overcome disease-poor response to conventional doses. So this approach deserves further evaluation as frontline therapy for newly diagnosed CML.

Address: Henan Tumor Hospital, Henan Institute of Haematology, Henan Medical School, Henan University, 127 Dongming Road, Zhengzhou 450008, China.

DOI: 10.1016/j.leukres.2007.02.004

Link outs

Free resources

Medical:

https://medlineplus.gov/chronicmyeloidleukemia.htm...

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Blast Crisis, Drug Resistance, Neoplasm, Drug Synergism, Female, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Middle Aged, Piperazines, Pyrimidines, Tetradecanoylphorbol Acetate, Treatment Outcome